Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GMDA

Gamida Cell (GMDA) Stock Price, News & Analysis

Gamida Cell logo

About Gamida Cell Stock (NASDAQ:GMDA)

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.40
52-Week Range
N/A
Volume
23.04 million shs
Average Volume
9.20 million shs
Market Capitalization
$5.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Gamida Cell Ltd. is a biotechnology company specializing in developing and commercializing innovative cell therapies. With a mission to transform the lives of patients with severe hematologic and solid tumor cancers, Gamida Cell is dedicated to harnessing the power of cell therapy to provide effective and personalized treatment options.

Headquartered in Jerusalem, Israel, Gamida Cell operates globally, focusing on developing and delivering breakthrough therapies to address significant unmet medical needs. The company's flagship product, Omidubicel, is an investigational advanced cell therapy designed to enhance the outcome of bone marrow transplantation and improve the standard of care for patients with hematologic malignancies.

Gamida Cell's products and services revolve around cell therapy, with a particular emphasis on expanding and enhancing the therapeutic potential of stem cells. By leveraging its proprietary NAM-based cell expansion technology platform, the company aims to increase the number and functionality of cells for transplantation, leading to improved patient outcomes.

The company primarily targets patients with blood cancers, including leukemia, lymphoma, and myeloma, where traditional treatment options often fall short. Gamida Cell's innovative approach has garnered recognition within the medical community and has received several notable achievements, milestones, and awards. For instance, in 2022, Gamida Cell was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Omidubicel, highlighting the therapy's potential to address a critical medical need.

It is important to note that stock performance is influenced by various factors, including news and events specific to the company. Recent news or events that may have affected Gamida Cell's share price include the publication of clinical trial data, regulatory updates, and announcements regarding partnerships or collaborations.

Looking beyond Gamida Cell's specific performance, it is essential to consider the broader industry in which the company operates. The field of cell therapy has been gaining significant attention and investment in recent years, driven by advancements in technology and the potential to revolutionize the treatment of various diseases, including cancer. Gamida Cell operates in a competitive landscape, with several other companies developing cell therapies and vying for market share.

As part of the industry analysis, it is crucial to evaluate Gamida Cell's competitive positioning and advantages relative to its peers. The company's proprietary NAM-based cell expansion technology platform sets it apart from competitors and positions it as a leader in the field. This technology allows for the expansion and enhancement of cells for transplantation, improving treatment outcomes and addressing critical unmet needs.

Gamida Cell's partnerships and collaborations with established pharmaceutical companies provide validation and access to resources that enhance its competitive advantage. These collaborations enable the company to leverage the expertise and resources of its partners to accelerate the development and commercialization of its cell therapy products.

While Gamida Cell has demonstrated growth and potential, it has risks and challenges. The biotechnology industry is highly regulated, and regulation changes or the regulatory environment can impact the development and approval of new therapies. The company must navigate complex and evolving regulatory pathways to successfully bring its products to market.

Additionally, Gamida Cell faces the challenge of staying ahead of the competition in a rapidly evolving field. Other companies also invest in cell therapies, and competitors' breakthroughs could threaten Gamida Cell's market position. Maintaining a robust research and development pipeline, protecting intellectual property, and securing strategic partnerships are vital for the company's long-term success.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Q4 2023 Gamida Cell Ltd Earnings Call
See More Headlines

GMDA Stock Analysis - Frequently Asked Questions

Gamida Cell Ltd. (NASDAQ:GMDA) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.13.

Gamida Cell (GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gamida Cell investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
8/14/2023
Today
12/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
143
Year Founded
N/A

Profitability

Net Income
$-63,000,000.00
Pretax Margin
-3,531.17%

Debt

Sales & Book Value

Annual Sales
$1.78 million
Book Value
($0.02) per share

Miscellaneous

Free Float
143,699,000
Market Cap
$5.04 million
Optionable
Optionable
Beta
0.93
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:GMDA) was last updated on 12/7/2024 by MarketBeat.com Staff
From Our Partners